It has previously been shown that patients with coronary artery disease may have a harder time quitting smoking if they have a specific genetic profile and that these individuals have a better chance at quitting if they receive nicotine replacement therapy. The investigators hypothesize that determining which individuals with coronary artery disease should receive nicotine replacement therapy based on their genotype may improve the number of individuals who are able to quit smoking.This study randomizes treatment to that determined by the patient's genotype compared to standard, non-genotype-guided, treatment.
Name: genotype-guided therapyDescription: treatment based on patient's CHRNA5 rs16969968 genotypeType: Other
Genotype-guided (A allele carriers) Genotype-guided (GG homozygotes)
Name: Nicotine patchType: Drug
Genotype-guided (A allele carriers) Standard (non-genotype guided) - NRT
Name: Smoking cessation counselingType: Behavioral
Genotype-guided (GG homozygotes) Standard (non-genotype guided)- counseling
Description: Number of participants no longer smoking as assessed by telephone-administered questionnaireMeasure: Smoking Cessation Time: 1 month after enrollment
Description: Number of participants no longer smoking as assessed by telephone-administered questionnaireMeasure: Smoking Cessation Time: 6 months after enrollment
Description: Number of participants no longer smoking as assessed by telephone-administered questionnaireMeasure: Smoking Cessation Time: 12 months after enrollment
There is one SNP
intubated) - Incarcerated - Complications of myocardial infarction (such as shock, hemodynamic instability, life- threatening infection, etc) - Women of child-bearing age with positive pregnancy test or who is breast feeding Coronary Artery Disease Smoking Cessation Coronary Artery Disease Myocardial Ischemia Coronary Disease In this study, the investigators propose to show the feasibility of incorporating genotype-guided therapy into post-MI smoking cessation therapy and/or smoking cessation therapy in patients with coronary artery disease (CAD) using the CHRNA5 rs16969968 variant as the pilot case.
The investigators propose to genotype ½ of PRISM-GENOMICs patients who are active smokers within 48 hours of admission and to guide their smoking cessation therapy based on CHRNA5 rs16969968 genotype (A allele carriers will be given pharmacologic therapy and GG homozygotes will be given counseling).